Evaluation of the performance of a lateral flow device for quantitative detection of anti-SARS-CoV-2 IgG

Introduction: The AbC-19™ lateral flow immunoassay (LFIA) performance was evaluated on plasma samples from a SARS-CoV-2 vaccination cohort, WHO international standards for anti-SARS-CoV-2 IgG (human), individuals ≥2 weeks infection of RT-PCR confirmed genetic variants, as well microorganism serology. Methods: Pre-vaccination to three post-booster were collected cohort 111 patients (including clinically extremely vulnerable patients) Northern Ireland. All received Oxford-AstraZeneca COVID-19 the first and second dose, Pfizer-BioNTech third (first booster). standards, 15 2 variants concern (Delta Omicron) cross-reactivity with other infections also assessed AbC-19™. Results: 80 (100%) participants sampled had high positive responses, compared 38/95 (40%) at 6 months post-first vaccination. standard results correlated information corresponding biological data sheets, antibodies all detected by LFIA. No found exception one (of five) Dengue virus samples. Conclusion: These findings suggest BNT162b2 booster enhanced humoral immunity pre-booster levels, that this antibody response detectable In combination cross-reactivity, variant would LFIA may be cost-effective measure assess status.